Paul Rubinstein, MD, discussed how cooperative groups are expanding CAR T and bispecific antibody research for patients with ...

Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.

Emory University Hospital was recently selected as the first medical center to adopt the Liberty endovascular robotic system, developed by Microbot Medical and granted 510(k) clea ...

A clinical trial of adjuvant intismeran (V940) with or without pembrolizumab coformulated with berahyaluronidase alfa ...

Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.

Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer. To better understand the potential clinical implications of ...

A growing number of anticancer therapies once available only as intravenous (IV) infusions now have subcutaneous formulations. These can shorten chair time for patients and change how infusion centers ...

Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer. In an interview with ...

The faculty then trace the development history of belantamab mafodotin. They describe the landscape around 2018, when daratumumab as a single agent produced a response rate close to 30% and only naked ...

Poster presentations at IMS 2026 highlighted the use of venetoclax, daratumumab, and different combination regimens across ...

Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC. The TRIPL trial (NCT06865339) is testing thoracic ...

Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain ...